Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
ACTIVE_NOT_RECRUITING
Status
Conditions
- Ann Arbor Stage III Hodgkin Lymphoma
- Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma
- Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma
- Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma
- Ann Arbor Stage IV Hodgkin Lymphoma
- Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma
- Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma
- Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma
- Classic Hodgkin Lymphoma
- Lymphocyte-Rich Classic Hodgkin Lymphoma
Interventions
- PROCEDURE: Biospecimen Collection
- DRUG: Brentuximab Vedotin
- PROCEDURE: Computed Tomography
- DRUG: Dacarbazine
- DRUG: Doxorubicin Hydrochloride
- BIOLOGICAL: Filgrastim
- PROCEDURE: Magnetic Resonance Imaging
- BIOLOGICAL: Nivolumab
- BIOLOGICAL: Pegfilgrastim
- PROCEDURE: Positron Emission Tomography
- OTHER: Quality-of-Life Assessment
- OTHER: Questionnaire Administration
- RADIATION: Radiation Therapy
- DRUG: Vinblastine Sulfate
Sponsor
National Cancer Institute (NCI)